A Study of Rofecoxib Versus Naproxen in the Treatment of Chinese Patient With Rheumatoid Arthritis (0966-231)

NCT00157872 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2017-05-25

No results posted yet for this study

Summary

A study to compare rofecoxib versus naproxen in the treatment of Chinese patients with rheumatoid arthritis.

Conditions

Interventions

DRUG

MK0966; rofecoxib

DRUG

Comparator: naproxen tablet 500 mg

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-07
Primary Completion
2004-07-05
Completion
2004-09-19

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00157872 on ClinicalTrials.gov